The move came after the Huons’ newly developed drug HU-014JU, which is designed to help smooth out forehead frown lines, got the green light from the Ministry of Food and Drug Safety for its first and second clinical trials in August.
“The product is set to enter the domestic market in 2018. We will push ahead with plans to get global approvals,” said Kim Wan-seop, senior executive at Huons Global.
The drug maker will also move forward with the treatment to win approval from the US Food and Drug Administration for its clinical trials next year.
Shares in the KOSDAQ-listed firm climbed 7.47 percent to close at 48,200 won.
By Park Han-na (firstname.lastname@example.org)